Aptinyx
2015
FOUNDED
PUBLIC
STATUS
61-70
EMPLOYEES
APTX
STOCK SYMBOL
$3.33
SHARE PRICE
(As of Friday Closing)
Description
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 909 Davis Street
- Suite 600
- Evanston, IL 60201
- United States
+1 (847) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Aptinyx’s full profile, request a free trial.
Aptinyx Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $3.27 - $32.25 | $112M | $3.33 | -$2.92 | 375K | 33.6M |
Aptinyx Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | (14,710) | 594,296 | ||
| Revenue | 5,000 | 6,574 | 4,962 | 9,792 |
| EBITDA | (57,849) | (52,824) | (31,663) | (15,293) |
| Net Income | (58,320) | (53,281) | (32,068) | (15,478) |
| Total Assets | 140,993 | 155,614 | 97,322 | 18,646 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Aptinyx Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Aptinyx‘s full profile, request access.
Request full access to PitchBookAptinyx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Aptinyx‘s full profile, request access.
Request full access to PitchBookAptinyx Competitors (12)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cortexyme | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Lexington, MA | 00 | 00000 | 000000000 | 00000 |
| 0000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 00000000 | 00000 |
| 0 000000000000 | Venture Capital-Backed | Salt Lake City, UT | 000.00 | 00000 00000 | 000.00 | |
| 000000 00000000000 | Venture Capital-Backed | Cambridge, MA | 0 | 000.00 | 00000000000 | 000.00 |
Aptinyx Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Aptinyx‘s full profile, request access.
Request full access to PitchBookAptinyx Executive Team (10)
You’re viewing 5 of 10 executives. Get the full list »Aptinyx Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Adam Koppel Ph.D | Bain Capital | Board Member | 000 0000 | |
| James Topper Ph.D | Frazier Healthcare Partners | Board Member | 000 0000 | |
| Liam Ratcliffe Ph.D | New Leaf Venture Partners | Board Member | 000 0000 | |
| Norbert Riedel Ph.D | Aptinyx | President, Chief Executive Officer & Board Member | 000 0000 | |
| Patrick Enright | Longitude Capital | Board Member | 000 0000 |
5 Former Board Members
You’re viewing 5 of 10 board members. Get the full list »